PMID- 25596071
OWN - NLM
STAT- MEDLINE
DCOM- 20160105
LR  - 20150317
IS  - 1437-7780 (Electronic)
IS  - 1341-321X (Linking)
VI  - 21
IP  - 4
DP  - 2015 Apr
TI  - The kinetics of the hepatitis B surface antigen level after the initiation of 
      antiretroviral therapy for hepatitis B virus and human immunodeficiency virus 
      coinfected patients.
PG  - 264-71
LID - S1341-321X(14)00417-6 [pii]
LID - 10.1016/j.jiac.2014.12.003 [doi]
AB  - BACKGROUND: Hepatic flares (HF), which reflect hepatitis B virus (HBV)-related 
      immune reconstitution inflammatory syndrome (IRIS), frequently occur in patients 
      with HBV and human immunodeficiency virus (HIV) coinfection after the start of 
      antiretoroviral therapy (ART). The rate of hepatitis B envelope antigen (HBeAg) 
      and hepatitis B surface antigen (HBsAg) loss is higher for patients with HF after 
      the initiation of ART. METHODS: We retrospectively examined the kinetics of the 
      HBsAg and HBeAg levels of six HBV/HIV coinfected patients after the commencement 
      of ART that included tenofovir. All were male and HBeAg positive. RESULTS: Three 
      patients developed HF after the initiation of ART. All subsequently lost HBeAg 
      and one of them lost HBsAg after HF. None who did not experience HF lost HBeAg. 
      The HBsAg and HBeAg levels remarkably decreased when HF occurred, but the decline 
      of HBsAg was very slow in the periods before and after HF. The median decline of 
      the HBsAg level at 48 weeks was 2.20 Log IU/mL for patients with HF, but only 
      1.00 Log IU/ml for patients without HF. Little decline was seen for either group 
      in the median decline of the HBsAg level from 48 weeks to 96 weeks, 0.28 Log 
      IU/mL in the HF group and 0.06 Log IU/mL in the non-HF group. CONCLUSION: The 
      immune reconstitution of a HBV/HIV coinfected patient plays an important role in 
      the clearance of HBV. If HBsAg and HBeAg levels decrease rapidly when HF occurs, 
      the hepatic flare would be due to HBV-related IRIS.
CI  - Copyright (c) 2014 Japanese Society of Chemotherapy and The Japanese Association 
      for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
FAU - Mitsumoto, Fujiko
AU  - Mitsumoto F
AD  - Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, 
      Japan.
FAU - Murata, Masayuki
AU  - Murata M
AD  - Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, 
      Japan. Electronic address: mmurata@gim.med.kyushu-u.ac.jp.
FAU - Ura, Kazuya
AU  - Ura K
AD  - Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, 
      Japan.
FAU - Takayama, Koji
AU  - Takayama K
AD  - Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, 
      Japan.
FAU - Hiramine, Satoshi
AU  - Hiramine S
AD  - Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, 
      Japan.
FAU - Shimizu, Motohiro
AU  - Shimizu M
AD  - Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, 
      Japan.
FAU - Toyoda, Kazuhiro
AU  - Toyoda K
AD  - Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, 
      Japan.
FAU - Ogawa, Eiichi
AU  - Ogawa E
AD  - Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, 
      Japan.
FAU - Furusyo, Norihiro
AU  - Furusyo N
AD  - Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, 
      Japan.
FAU - Hayashi, Jun
AU  - Hayashi J
AD  - Kyushu General Medicine Center, Haradoi Hospital, Fukuoka, Japan.
LA  - eng
PT  - Journal Article
DEP - 20141218
PL  - Netherlands
TA  - J Infect Chemother
JT  - Journal of infection and chemotherapy : official journal of the Japan Society of 
      Chemotherapy
JID - 9608375
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (DNA, Viral)
RN  - 0 (Hepatitis B Surface Antigens)
RN  - 0 (Hepatitis B e Antigens)
RN  - 0 (RNA, Viral)
RN  - 99YXE507IL (Tenofovir)
SB  - IM
MH  - Adult
MH  - Anti-Retroviral Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Coinfection/drug therapy/epidemiology/*virology
MH  - DNA, Viral/blood
MH  - Female
MH  - HIV Infections/*drug therapy/epidemiology
MH  - Hepatitis B/complications/drug therapy/epidemiology/*virology
MH  - Hepatitis B Surface Antigens/*blood
MH  - Hepatitis B e Antigens/*blood
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome
MH  - Kinetics
MH  - Male
MH  - Middle Aged
MH  - RNA, Viral/blood
MH  - Retrospective Studies
MH  - Tenofovir/administration & dosage/pharmacology/therapeutic use
MH  - Viral Load
MH  - Young Adult
OTO - NOTNLM
OT  - Hepatitis B surface antigen
OT  - Hepatitis B virus
OT  - Human immunodeficiency virus
OT  - Immune reconstitution inflammatory syndrome
EDAT- 2015/01/18 06:00
MHDA- 2016/01/06 06:00
CRDT- 2015/01/18 06:00
PHST- 2014/09/30 00:00 [received]
PHST- 2014/11/26 00:00 [revised]
PHST- 2014/12/05 00:00 [accepted]
PHST- 2015/01/18 06:00 [entrez]
PHST- 2015/01/18 06:00 [pubmed]
PHST- 2016/01/06 06:00 [medline]
AID - S1341-321X(14)00417-6 [pii]
AID - 10.1016/j.jiac.2014.12.003 [doi]
PST - ppublish
SO  - J Infect Chemother. 2015 Apr;21(4):264-71. doi: 10.1016/j.jiac.2014.12.003. Epub 
      2014 Dec 18.